BORTEZOMIB (VEL) BASED REGIMENS IN MULTIPLE MYELOMA (MM) PATIENTS WITH RENAL IMPAIRMENT (RI): A PRELIMINARY RETROSPECTIVE ITALIAN MULTICENTER STUDY

被引：0
|
作者：
Gentile, M. [1 ]
Ciolli, S. [2 ]
Petrucci, M. T. [3 ]
Galimberti, S. [4 ]
Mele, G. [5 ]
Casulli, A. F.
Mannina, D. [6 ]
Piro, E. [7 ]
Morabito, F. [1 ]
机构：
[1] Ematol Cosenza, Cosenza, Italy
[2] Univ & Osped Careggi, Dipartimento Ematol, Florence, Italy
[3] Univ Roma La Sapienza, Dipartimento Biotecnol & Ematol, Rome, Italy
[4] Osped Santa Chiara, Sez Ematol, Dipartimento Oncol, Pisa, Italy
[5] Presidio Osped A Perrino, Div Ematol, Brindisi, Italy
[6] Azienda Osped Papardo, Div Ematol, Taranto, Italy
[7] Osped Pugliese Ciaccio, Div Ematol, Catanzaro, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0210
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [41] SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) BORTEZOMIB IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (MM): SUBANALYSIS OF PATIENTS WITH RENAL IMPAIRMENT IN THE PHASE 3 MMY-3021 STUDY
    Moreau, P.
    Pylypenko, H.
    Grosicki, S.
    Karamanesht, I.
    Leleu, X.
    Rekhtman, G.
    Robak, P.
    Esseltine, D. L.
    Feng, H.
    Deraedt, W.
    van de Velde, H.
    Arnulf, B.
    HAEMATOLOGICA, 2014, 99 : 361 - 361
  • [42] The effect of bortezomib monotherapy and bortezomib-based regimens on bone metabolism in patients with relapsed/refractory multiple myeloma
    Terpos, E.
    Heath, D. J.
    Zervas, K.
    Anagnostopoulos, A.
    Katodritou, E.
    Christoulas, D.
    Pouli, A.
    Chantry, A.
    Anargyrou, K.
    Kastritis, E.
    Verrou, E.
    Tsionos, K.
    Croucher, P.
    Dimopoulus, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 133 - 134
  • [43] Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma
    Lamm, W.
    Drach-Schauer, B.
    Eder, S.
    Drach, J.
    ONCOLOGY, 2013, 85 (04) : 223 - 227
  • [44] EFFICACY AND SAFETY OF BORTEZOMIB-BASED RETREATMENT IN MULTIPLE MYELOMA (MM) PATIENTS RELAPSING AFTER BORTEZOMIB-CONTAINING FIRST-LINE THERAPY: A RETROSPECTIVE STUDY
    Oriol, A.
    Giraldo, P.
    Kotsianidis, I.
    Couturier, C.
    Angermund, R.
    Broer, E.
    Corso, A.
    HAEMATOLOGICA, 2012, 97 : 609 - 610
  • [45] RECOVERY OF RENAL IMPAIRMENT BY BORTEZOMIB-DOXORUBICIN-DEXAMETHASONE (BDD) IN MULTIPLE MYELOMA (MM) PATIENTS WITH ACUTE RENAL FAILURE. RESULTS FROM AN ONGOING PHASE II STUDY
    Ludwig, P.
    Adam, Z.
    Greil, R.
    Keil, F.
    Zojer, N.
    Thaler, J.
    Gisslinger, H.
    Lang, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 177 - 177
  • [46] Recovery of renal impairment by bortezomib-doxorubicin-dexamethasone (BDD) in multiple myeloma (MM) patients with acute renal failure. Results from an ongoing phase II study
    Ludwig, Heinz
    Adam, Zdenek
    Hajek, Roman
    Greil, Richard
    Keil, Felix
    Zojer, Niklas
    Thaler, Josef
    Gisslinger, Heinz
    Lang, Alois
    BLOOD, 2007, 110 (11) : 1054A - 1054A
  • [47] Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study
    Anderson, K. C.
    Weller, E.
    Lonial, S.
    Jakubowiak, A. J.
    Jagannath, S.
    Raje, N. S.
    Avigan, D.
    Knight, R. D.
    Esseltine, D.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] A Systematic Review on the Use of Bortezomib in Multiple Myeloma Patients with Renal Impairment: What Is the Published Evidence?
    Piro, Eugenio
    Molica, Stefano
    ACTA HAEMATOLOGICA, 2011, 126 (03) : 163 - 168
  • [49] Survival of Patients with Multiple Myeloma That Is Refractory to Both Bortezomib and Lenalidomide: A Retrospective Study
    Miyazaki, Kanji
    Suzuki, Kenshi
    BLOOD, 2018, 132
  • [50] Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry
    Ailawadhi, Sikander
    Lee, Hans C.
    Omel, James
    Toomey, Kathleen
    Hardin, James W.
    Gasparetto, Cristina J.
    Jagannath, Sundar
    Rifkin, Robert M.
    Durie, Brian G. M.
    Narang, Mohit
    Terebelo, Howard R.
    Joshi, Prashant
    Jou, Ying-Ming
    Mouro, Jorge
    Yu, Edward
    Abonour, Rafat
    BLOOD CANCER JOURNAL, 2024, 14 (01):
12345